MREO   $1.23  2.48% Market Closed

Mereo Biopharma Group PLC
Last Events:

2023-05-03 Signal in MACD changed from bullish recovery to bullish weakening. Oscillator MACD is in the positive territory it's higher than the signal line and falls. These factors mean that the growing trend persists, but the growth rate is declining. Last signal: signal line crossed the middle level.

2023-05-02 Signal in Stochastic changed from bullish to bearish reversal. The stochastic indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: main and signal line crossing.

2023-05-02 Signal in RSI changed from bullish recovery to bearish reversal. RSI indicator is in the upper part of the neutral territory and left the overbought territory. These factors indicate that perhaps the upside trend is coming to an end price will probably head south Last signal: entrance to the overbought zone.

2023-05-02 Trend Power changed from slow to almost flat.

2023-04-29 Signal in RSI changed from bearish reversal to bullish recovery. RSI indicator is in overbought territory and it heading north. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: entrance to the overbought zone.

2023-04-29 Trend Power changed from almost flat to slow.

2023-04-28 Trend pattern changed from канал to расходящийся клин с наклоном вниз.

2023-04-28 Signal in Stochastic changed from bearish to bullish. The stochastic indicator is in overbought territory and it grows. These factors indicate that the upside potential still holds even though the market is overbought. Last signal: signal line crossed the middle level.


Current temperature: 2.27
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 350.20
Mean unverified/preliminary 350.20 / 350.20
Target Price Low / High 323.26 / 404.07
Median / STD DEV 323.26 / 46.66
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - Sell -
stoch Sell - -
ma20 Sell Sell Sell
ma50 Sell - -
ma100 - Sell Sell
Candlestick PatternMay 1, 2023 Dark Clouds Cover - is a candlestick pattern whereby a black candlestick opens above a white candlesticks close and below its midpoint.Considered to be a bearish reversal pattern.
ISIN US5894921072
ceo Dr. Denise Vera Scots-Knight Ph.D.
Website https://www.mereobiopharma.com
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.